Gene expression profiling upon treatment with NTX-301 in MV4-11. Gene expression profiling upon treatment with NTX-301 in MV4-11

A novel hypomethylating agent NTX-301 is a promising therapeutic agent for AML patients. To examine its mechanisms of action, we produced gene expression data upon treatment with NTX-301 or decitabine (DAC) in MV4-11 cell line. Overall design: MV4-11 leukimia cells were cultured using the RPMI1640 medium. Cells were plated on 6-well plates at the day before drug treatment, and DMSO, NTX-301 (60nM), and DAC (60nM) were treated during 48, 96h. After extracting Total RNA and assessing RNA purity and integrity by ND-1000 Spectrophotometer, the RNA samples were applied to the Affymetrix Whole transcript Expression microarray according to the manufacturer's protocol (Affymetrix GeneChip Human 2.0 ST Array).